Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, Michigan, USA
ORYGEN Research Centre, Department of Psychiatry, The University of Melbourne, Parkville, Australia
Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Canada
Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne, Parkville, Australia
Correspondence: Dr Matcheri S. Keshavan, Department of Psychiatry and Behavioral Neurosciences, Wayne State University, UCH 9B, 4201 St Antoine Boulevard, Detroit, Michigan, USA. Tel: +1 313 993 6732; fax: +1 313 577 5900; e-mail: mkeshava{at}med.wayne.edu
* Paper presented at the Third International Early Psychosis Conference,
Copenhagen, Denmark, September 2002.
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Aims To review the recent literature on the biology of the early course of psychoses.
Method We carried out a critical appraisal of the recent findings in the neurobiology of early psychoses, using structural, functional and neurochemical imaging techniques.
Results Brain structural alterations are present early in the illness and may predate symptom onset. Some changes, notably those in frontal and temporal lobes, can progress during the early phases of the illness. Functional and neurochemical brain abnormalities can also be seen in the premorbid and the early phases of the illness. Some, although not all, changes can be trait-like whereas some others might progress during the early years.
Conclusions A better understanding of such changes, especially during the critical periods of the prodrome, around the transition to the psychotic phase and during the early phases of the illness is crucial for continued research into preventive intervention strategies.
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Studies of individuals in the early phases of schizophrenia avoid such confounds and allow us to elucidate the effects of primary illness processes (Keshavan & Schooler, 1992). First, these studies allow prospective longitudinal evaluation of the course and predictive value of the neurobiological changes. Most neurobiological studies in early psychosis do not consider the heterogeneity of the initial presentation, and this may explain some of the contradictory findings. Early psychosis represents a broad range of possible diagnostic and prognostic categories that include, but are not limited to, the more traditionally studied schizophrenia and schizoaffective disorder. Only about half of patients with early psychosis (Harding et al, 1987; Moller & Von Zerssen, 1995) will develop a chronic form of schizophrenia with poor levels of functioning and major impairment in cognition. Second, not everyone who has features of the prodromal phases of the illness goes on to develop the psychotic illness. Studies of the prodromal and early course of psychotic disorders provide an opportunity to elucidate the neurobiological mechanisms responsible for the transition from the prodrome to schizophrenia or other psychotic disorders.
The importance of studying the neurobiology of early psychosis stems from the recent emphasis on early identification and preventive intervention in disorders such as schizophrenia (Wyatt, 1991; Lieberman et al, 2001). The onset of psychotic symptoms in schizophrenia is often preceded by a premorbid phase, characterised by subtle neuromotor and cognitive impairments that may date back to birth. The prodromal phase is associated with cognitive impairment, affective symptoms, social withdrawal, and/or sub-threshold (attenuated) positive symptoms. Recent studies suggest that more than a third of patients presenting with prodromal symptoms, if untreated, convert to schizophrenia or a related psychotic disorder (McGorry et al, 2002; Yung et al, 2003). The duration of the psychotic symptoms prior to treatment typically averages about a year, and the average prodromal duration is about 3 years across studies (McGlashan, 1996). If untreated, the early phases of schizophrenia result in a progressive accrual of morbidity; the longer the period of untreated illness, the worse appears to be the outcome (Lieberman et al, 2001; McGorry et al, 2001; Keshavan et al, 2003a). Studies of patients at ultra-high risk of psychosis and in the early phase schizophrenia and related disorders are critical for our prevention and early intervention efforts, since the deteriorative processes of this illness may set in during this critical time window (McGlashan, 1996).
Neurobiological investigations in early psychosis have greatly benefited from recent conceptual models that have suggested a number of testable hypotheses. The traditional (or early) neurodevelopmental model posits abnormalities in foetal brain development as mediating the failure of brain functions in early adulthood. An array of data, such as an increased rate of obstetric complications, minor physical abnormalities, neurological soft signs and subtle behavioural abnormalities in children who later developed schizophrenia, support this model for schizophrenia in particular, but most likely also for a range of other neuropsychiatric disorders. However, their prevalence in the non-affected population is substantial and their positive predictive value for the development of schizophrenia is limited (Murray & Lewis, 1987; Weinberger, 1987). The illness onset, typically in adolescence and early adulthood, is suggestive of brain maturational abnormality around or prior to the onset of psychosis. Excessive synaptic/dendritic pruning around the peri-onset phase of illness (Feinberg, 1982, 1990; Keshavan et al, 1994) has been postulated as one potential pathological mechanism underpinning the onset of psychosis in adolescence or early adulthood, but the understanding of the underlying neurobiology of this phase of illness is still limited. The idea that active biological changes could occur during the prodromal phase or the often lengthy period of untreated psychosis has led to the neurodegenerative models (Garver, 1987; McGorry & McConville, 2000; Lieberman et al, 2001). Unifying models have also been proposed and include two (Bayer et al, 1999) and three hit models (Keshavan & Hogarty, 1999; Velakoulis et al, 2000; Pantelis et al, 2003c) of schizophrenia; environmental factors, such as illicit drug use and psychosocial stress, also may be the potential secondary triggers accompanying the onset and course of schizophrenia (Allin & Murray, 2002; Buhler et al, 2002). Neurobiological studies of early psychoses have the potential to examine predictions generated by these seemingly contrasting models.
![]() |
METHOD |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Earlier cross-sectional CT and MRI studies failed to find a relationship between illness duration and brain findings in chronically ill subjects (Zipursky et al, 1988; Marsh et al, 1994). In a more recent study Hulshoff Pol et al (2002) used MRI to study whole brain grey matter volumes over the adult age range in 159 patients with schizophrenia and 158 healthy comparison subjects. They found a significant group-by-age interaction with grey matter volumes declining at a more rapid rate in patients with schizophrenia. In another study of patients with established schizophrenia that examined brain grey matter using a voxel-based analysis method, Velakoulis et al (2000) found that duration of illness was associated with a reduction in grey matter volume in the right medial temporal lobe and medial cerebellum, and the anterior cingulate bilaterally. With this study design, however, it is not possible to know whether this effect can be explained by sampling bias (i.e. the older the patients, the more likely they are to be drawn from poor outcome chronically ill samples) or whether this reflects progressive changes that one might actually see within individuals over time.
It could be the case that being psychotic is in some way toxic to the brain and that by controlling the psychosis with antipsychotic medication, the progression of brain abnormalities might be limited. An MRI study in never-treated chronic schizophrenia patients (ill for over 10 years) in South India (McCreadie et al, 2002) found no association between illness duration and ventricular volume. Ho et al (2003) studied 156 patients with a first episode of schizophrenia and also failed to detect any significant correlations between duration of untreated psychosis and brain volumetric measures. Alternatively, the progression of brain changes might be self-limiting, with maximal differences achieved in the first years of the illness. Pursuing this possibility requires studying patients early in the course of their illness and carrying out follow-up scans.
Studies of first-episode schizophrenia (Lim et al, 1996; Zipursky et al, 1998) suggest that patients with first-episode psychosis differ from healthy comparison individuals on structural brain measures, but less so than observed in samples of chronically ill patients with schizophrenia. At first glance, this might seem to support the view that progression of these abnormalities is taking place over the course of the illness. As suggested above, an equally tenable possibility is that a selection effect may be taking place by which subjects with more pronounced brain differences early in their illness might be more likely to find themselves in a poor outcome chronically ill group (Zipursky et al, 1998). Longitudinal studies are required in order to distinguish between these two hypotheses.
Longitudinal follow-up studies of patients with first-episode psychosis have yielded conflicting results. Gur and colleagues described changes in MRI measures in 20 patients with first-episode schizophrenia, 20 previously treated patients and 17 controls studied twice over periods ranging from 12 to 68 months (Gur et al, 1998); patients with first-episode psychosis had more pronounced left frontal lobe volume reductions than previously treated patients and greater bilateral tissue reductions in the temporal lobes. However, greater reductions in frontal and temporal volumes were highly correlated with greater medication doses in the patients with first-episode psychosis but not in previously treated patients. Wood et al (2001) in their longitudinal MRI study of 30 patients with first-episode psychosis, 12 patients with established schizophrenia and 26 control subjects identified significant reductions in whole brain volume that were most apparent in the early phase of the illness and showed a greater loss with greater inter-scan interval over a 4-year period. In a recent more detailed analysis of this cohort, this loss of brain volume was explained by grey matter loss in dorsal prefrontal and parietal cortical regions (Sun et al, 2003). Cahn et al (2002) have described decreases in total grey matter volume and increases in lateral ventricle volume in 34 patients with first-episode schizophrenia compared with 36 healthy comparison subjects scanned over a 1-year interval. The decrease in global grey matter volume was, however, significantly correlated with higher cumulative doses of antipsychotic medication. That the association between medication dose and duration has not been evident in studies of more chronically ill patients suggests that there may be a ceiling effect such that once the differences are apparent early in treatment, little further progression takes place (Lieberman et al, 2003).
Medications may explain some, but not all, of the structural brain abnormalities reported in schizophrenia. Differences in ventricular volume have been reported in studies prior to the introduction of antipsychotic medications in never-treated patients (McCreadie et al, 2002) and in unaffected (and untreated) family members (Cannon et al, 1998; Sharma et al, 1998). Smaller intracranial volumes have been reported in both affected and unaffected monozygotic twins who are discordant for schizophrenia, suggesting that genetic risk may contribute to the expression of the brain abnormalities reported in schizophrenia (Baare et al, 2001).
That brain findings are present at the time of the first episode does not establish that they have been present or stable since birth. Just as schizophrenia may evolve through a prodromal stage in many individuals, it is possible that the brain changes are also evolving during this time and driving the clinical deterioration characteristic of the prodromal period. The recent interest in identifying individuals at ultra-high risk for developing psychosis (Phillips et al, 2002) allows imaging of patients prior to and after emergence of the illness and there by study of the neurobiology of transition to psychosis. Individuals at genetic risk for developing schizophrenia had smaller volumes of the left amygdalahippocampal complex and thalamic nuclei than controls (Lawrie et al, 2001; Keshavan et al, 2002a). In the Edinburgh High Risk Study, over a 2-year follow-up period, at-risk participants as a group did not show greater regional brain volume changes than healthy controls, although at-risk participants with psychotic symptoms showed greater changes over the follow-up period than those without psychotic symptoms (Miller et al, 2002). Pantelis et al (2003a) carried out a longitudinal study of individuals treated in the PACE clinic in Melbourne, a specialist service for people at ultra-high risk for psychosis (for definition of criteria see Yung et al, 1996), which involved baseline and 12-month follow-up scans. Of the 75 participants who had a baseline scan, 23 developed psychosis and 52 did not. At their initial scan, those who later became psychotic had less grey matter in the right medial temporal, lateral temporal and inferior frontal cortex and in the cingulate cortex bilaterally. Ten individuals who were rescanned had developed psychosis in the follow-up period and 11 had not. Grey matter volume reductions were more pronounced in those who became psychotic, suggesting that an active disease process may be taking place in the brain. Some of the patients received antipsychotic medication in the interval between scans, so treatment cannot be ruled out as an explanation for the differential changes found in those who became psychotic. The absence of an age-matched healthy comparison group further limits the interpretation of this study. New techniques, such as diffusion tensor imaging, may provide important opportunities to study brain development longitudinally in individuals in the early stages of schizophrenia (Begre et al, 2003).
Cognition, electrophysiology and functional neuroimaging studies
In general, cognitive studies of early psychosis have mirrored the findings
in chronic schizophrenia, with a similar pattern of impairments in executive
function, attention and memory being identified
(Heinrichs & Zakzanis,
1998). However, the magnitude of the impairments found in some of
these studies indicates a smaller magnitude of deficits, although this may
depend on the particular domain being examined. This has been shown both when
tests are organised into sub-batteries by domain (e.g.
Hoff et al, 1992;
Bilder et al, 2000)
and when individual tests are examined
(Mohamed et al,
1999). There has, however, been debate about whether the
impairment is generalised or whether there is evidence of a difference between
cognitive domains (despite the similarity in results). Some studies (e.g.
Mohamed et al, 1999)
suggest that although small differences can be found between different
domains, the effect size of the differences between domains is overshadowed by
the much larger effect size of the difference between the patients and the
controls (in the Mohamed et al study the largest effect size for
differences between domains was 0.52, but for the difference between
patients and controls 25 out of 30 tests had a Cohens d of
greater than 0.75). Although this may be partly attributed to poor matching of
tests assessing different domains, it also suggests that the difference
between domains might not be clinically meaningful. Other authors have
suggested that although a generalised deficit is present, there is a
differential impairment. This is most often found to be in the area of memory
and learning (e.g. Saykin et al,
1994; Hutton et al,
1998) although the domains of attention and/or executive skills
are also the lower scores in the profile (e.g.
Albus et al, 1996).
Saykin et al (1994)
and Bilder et al
(2000) utilised standardised
residualised scores as a means to overcome the problems associated with poorly
matched tasks. They both found that verbal memory and learning scores were
lower than predicted on the basis of other scores, providing support for a
differential impairment. In contrast, in the study by Weickert et al
(2000), in which groups of
patients were defined according to the extent of a generalised intellectual
impairment, consistent deficits on the Wisconsin Card Sorting Test (WCST) were
found, providing further evidence for differential impairment in executive
function.
Such data, supporting a differential rather than generalised impairment, are also consistent with the findings from brain structural (described above) and functional imaging studies implicating regions of the prefrontal cortex and their connections with other areas, particularly subcortical and limbic regions (Liddle et al, 2000; Pantelis et al, 2002). The most consistent finding in schizophrenia has been of hypofrontality, which is most apparent when patients are tested while undertaking neuropsychological tasks relevant to the prefrontal cortex (Velakoulis & Pantelis, 1996; Davidson & Heinrichs, 2003), although this notion has been challenged (Manoach et al, 1999; Callicott et al, 2000). In their meta-analysis of 155 structural (MRI) and functional (positron emission tomography and single photon emission tomography) imaging studies of frontal and temporal lobe regions, Davidson & Heinrichs (2003) found that hypofrontality during cognitive activation showed the strongest effect and distinguished approximately half of schizophrenia patients from healthy controls (Cohens d= 0.81; for resting studies, d= 0.65), whereas temporal lobe function did not discriminate the groups. In contrast, for structural imaging, the largest effect sizes were found for left superior temporal gyrus and left and right hippocampal volumes (d= 0.55, 0.55, 0.58, respectively). A preliminary meta-analysis of 14 functional MRI studies found that resting scans, regardless of cognitive task use, differed between patients with schizophrenia and control individuals, whereas patients displayed less robust activation to cognitive challenge (Kindermann et al, 1997). Although such meta-analyses are informative, available studies have not been able to address some key questions, including: (a) other brain regions in which abnormal function has been identified (e.g. Carter et al, 1997; Haznedar et al, 1997; Yucel et al, 2002); (b) the interaction between different regions that is currently relevant to the notion of disturbed connectivity (e.g. Fletcher et al, 1999); and (c) the relationship between structural and functional imaging measures (e.g. Weinberger et al, 1992; Bertolino et al, 2000; Bilder et al, 2000; Callicott et al, 2000). Further, meta-analyses have not addressed the importance of controlling for behavioural performance on tasks used during activation studies. For example, in the studies by Manoach et al (1999) and by Callicott et al (2000) patients showing only a slight impairment in performance on graded tasks of executive function had greater rather than less activation in dorsal prefrontal cortex.
The current functional imaging literature is also limited in addressing issues such as illness stage and medication-related effects, as there are relatively few studies in the earliest stages of psychosis, especially in neuroleptic-naïve or unmedicated patients and even fewer in high-risk populations. In the resting study of 70 unmedicated patients with schizophrenia, who had at least 4 weeks off medication, Siegel and colleagues (Miller et al, 2002), found reduced activity in medial rather than dorsal prefrontal cortex and in associated regions of striatum and thalamus. Similarly, Stevens et al (1998) found that inferior and ventral regions were hypofunctioning. However, such studies do not take account of the long-term effects of medication and illness duration. In contrast, Barch et al (2001), in their well-designed functional MRI study examined neuroleptic-naïve first episode patients with schizophrenia using a context-dependent working memory task and found that dorsolateral prefrontal cortex, rather than other prefrontal regions, was specifically implicated from the outset of illness. These results are consistent with the findings of impaired working memory deficits in first-episode psychosis (Hutton et al, 1998; Proffitt et al, 2000; Wood et al, 2002). Two other studies in neuroleptic-naïve patients confirmed hypofrontality at illness onset (Parellada et al, 1998; Riehemann et al, 2001). The only available functional imaging study in a high-risk prepsychotic sample is consistent with the findings at illness onset (Keshavan et al, 2002b), which is also consistent with deficits in working memory in a similar population (Wood et al, 2003).
In parallel with the debate about whether brain structural abnormalities are static or progressive, various studies have assessed the stability of cognitive deficits over time and a few recent studies have examined change in brain function longitudinally. While the comparison of first episode with chronic patients suggests some decline in function, longitudinal studies have found little change over the years following the first episode (Censits et al, 1997; Gold et al, 1999; Hoff et al, 1999). In addition, a meta-analytical study of memory (Aleman et al, 1999) found little difference in effect size between studies with chronic compared with first-episode populations. Relationships have been identified between change in clinical symptoms and change in neuropsychological scores. For example, some studies (Censits et al, 1997; Gold et al, 1999; Brewer et al, 2001; Schuepbach et al, 2002) have found that change in negative symptoms is associated with change in neuropsychological scores, whereas another (Hoff et al, 1999) found a similar relationship with change in positive symptoms. These studies need to be interpreted with caution, particularly as few have distinguished between primary and secondary negative symptoms (Kirkpatrick et al, 2001). Overall, the longitudinal and some cross-sectional studies (e.g. meta-analyses that compare the effect size associated with first-episode and chronic schizophrenia) support the view that fairly extensive cognitive deficits are present by the first episode of psychosis and that they are likely to be a stable, ongoing, trait-like feature of the persons illness. This impairment appears to be relatively unaffected by the persons level of clinical symptoms.
In this context, it is worth noting the unreliability of the term first episode and the potential implications this has for defining the onset of the cognitive deficits in psychosis. The term first episode has been used to cover a relatively long period of time. For example, in the Bilder et al (2000) study, 21% of participants were tested more than a year after the onset of treatment, while the mean illness duration in the Saykin et al (1994) study was 2 years. This is further confused by the fact that the term illness duration could be used to cover the duration of untreated psychosis before contact with the psychiatric service. Caution in accurately defining the term first episode is needed to ensure that active changes are occurring in the earliest phase of illness. For example, in a recent study of the cognitive abilities of patients with first-episode psychosis who were within 6 months of psychosis onset, in comparison with a group of patients with chronic schizophrenia and normal control participants (Wood et al, 2002), the patients with first-episode psychosis had no impairment on a visual associative memory task, whereas patients with chronic schizophrenia were significantly impaired. In contrast, the impairments of both patient groups on a spatial working memory task were very similar. This suggests that there may be some differential impairment in cognitive function over the illness course, with some present at or prior to the onset of the disorder, whereas others arise with prolonged psychosis. Clearly, longitudinal studies are needed from the earliest phase of psychotic disorders to elucidate whether deficits develop as the illness progresses. The limited available longitudinal functional imaging studies have focused on the effects of medication, and have demonstrated differences between typical and atypical antipsychotics (Honey et al, 1999; Liddle et al, 2000; Miller et al, 2001), suggesting some consistency with the neuropsychological studies that have identified improvement in neuropsychological function with atypical neuroleptics (Meltzer & McGurk, 1999; Bilder et al, 2002).
Another approach that is helpful in addressing the issue of whether neuropsychological and functional impairments are stable trait features of schizophrenia and psychosis is to examine neuropsychological and brain activity in prepsychotic, high-risk, individuals. Neuropsychological investigations have been performed as part of investigations, including the long-term high-risk studies that followed children into adulthood, such as the New York, Stony Brook, Copenhagen and Israeli High-Risk Studies, whereas more recent strategies, exemplified by the Edinburgh High Risk, and Melbourne Ultra High-Risk Studies, have used alternative approaches in order to increase the yield and reduce the period of follow-up required. Various groups have adopted the ultra-high risk strategy and results on neuropsychological functioning from these studies are beginning to emerge (Cornblatt, 2002; Hambrecht et al, 2002; Brewer et al, 2003; Wood et al, 2003). The early high-risk studies are summarised elsewhere in special issues of Schizophrenia Bulletin in 1985 (vol. 11, issue 1) and 1987 (vol. 13, issue 3). Briefly, with respect to neuropsychology these earlier studies focused on attention, with more limited information available with respect to other cognitive domains (Weintraub, 1987; Mirsky et al, 1995; Wolf & Cornblatt, 1996). The New York High-Risk Study has been most informative in this respect, with the demonstration that childhood deficits in attention, motor skills and shortterm memory, measured at 712 years of age, identified 58%, 75% and 83% (respectively) of those who later developed a schizophrenia-related psychosis (Erlenmeyer-Kimling et al, 2000). However, other groups have only partly replicated these findings. The Edinburgh High Risk Study found that verbal memory and executive function did distinguish between young relatives with and without psychotic symptoms during follow-up; other cognitive measures showed few clear differences (Cosway et al, 2002). This lack of replication may depend on the domains assessed and the timing of the assessment (Andersen, 2003; Pantelis et al, 2003c; Wood et al, 2003).
The more recent studies have comprehensively assessed neuropsychological function, although not all data have been published as yet. In the studies by the Edinburgh group, slightly lower levels of global cognitive function were identified in a high-risk cohort than in a group of matched controls (Byrne et al, 1999). When this difference was controlled for, the high-risk group was significantly impaired only on a global memory test and on a sentence completion test that implicates executive functions. However, none of the participants in that study had become acutely psychotic at the time of publication, which highlights one of the problems of research in high-risk populations, namely, that it will remain unclear to what extent neuropsychological deficits identified premorbidly are predictive of the later onset of schizophrenia until there has been an adequate follow-up period to determine who will develop psychosis, such as in the New York High-Risk Study discussed above. Another approach has been to identify cases from long-term population-based follow-up studies, as in the Dunedin Multidisciplinary Health and Development Study (Poulton et al, 2000), which identified reduced intelligence and receptive language skills in children between the ages of 3 and 9 years who later fulfilled criteria for schizophreniform disorder (Cannon et al, 2002). Although difficult to set up and undertake, such an approach is particularly informative as it does not focus only on the offspring of patients with schizophrenia. Although these studies provide evidence that early neuropsychological deficits may be markers of impending illness later in life, the question of specificity of these findings to schizophrenia remains unclear.
In order to address the long follow-up period required and the low number of individuals developing psychosis in the high-risk and population-based studies described, the Melbourne group have utilised an ultra-high-risk strategy to identify young people at imminent risk of developing a psychotic illness. Using this approach about 40% of individuals make the transition to psychosis within 12 months of presentation (Yung et al, 1998). Initial findings (including neuroimaging findings described earlier) at baseline, prior to illness transition, have identified deficits in spatial working memory ability in those who subsequently developed psychosis (Wood et al, 2003), which were similar to those observed in patients with schizophreniform psychosis and established schizophrenia (Wood et al, 2002). Deficits in olfactory function are also found specifically in those developing schizophrenia (Brewer et al, 2003). In contrast, preliminary findings indicate that some other aspects of memory are not impaired (Pantelis et al, 2003b). These data, taken together with findings in patients with first-episode and chronic psychosis using the same tasks, provide further evidence that particular domains of function are differentially impaired, and raise the possibility that other domains may only become apparent as the illness develops a more chronic course.
A complementary approach to examining brain function uses event-related brain potentials (ERPs), which can track changes in brain functioning over a short period of time, thereby providing dynamic information about the progression of brain activity during cognitive tasks. Although a number of ERP components have been studied in schizophrenia, most work in early psychosis has focused on mismatch negativity and P300 (for review see Salisbury et al, 2003). The mismatch negativity is a negative auditory ERP, occurring 150250 ms after presentation of deviant stimuli, which are elicited by interspersing infrequent sounds (differing in pitch, duration, intensity or spatial location) in a sequence of repetitive sounds. The mismatch negativity is evoked automatically, is preconscious, is thought to have generators in auditory cortices but may also have a prefrontal generator (Salisbury et al, 2003), and may reflect activity of N-methyl-D-aspartate (NMDA) receptors (Umbricht et al, 2000, 2003). Mismatch negativity is reduced in patients with established schizophrenia (Catts et al, 1995; Javitt et al, 2000b), has been shown to be specific to schizophrenia (Catts et al, 1995; Umbricht et al, 2003), and these deficits (considered to reflect transient memory traces) have been related to impaired performance on an attentional task (Javitt et al, 2000b). In contrast, patients with first-episode psychosis early in their course of illness are unimpaired (Salisbury et al, 2002), whereas patients within the first 3 years of illness show a mild deficit (Javitt et al, 2000a). Preliminary longitudinal findings of a small sample of patients over the first 2 years of illness have been presented by Salisbury et al (2001), and these authors consider that the mismatch negativity may index progressive neurodegeneration in schizophrenia, involving superior temporal gyrus (Salisbury et al, 2003), which may be mediated by NMDA (Olney et al, 1999). However, a genetic contribution has also been suggested by recent evidence that patients with schizophrenia and their first-degree relatives show deficits in mismatch negativity (Michie et al, 2002), but Jessen et al (2001) found that relatives were impaired but patients did not differ from controls. Further, in a study of children at high risk for schizophrenia, mismatch negativity showed some reduction (Schreiber et al, 1992). These findings indicate that further studies from the earliest phase of psychosis, in prepsychotic individuals, and studies of unaffected family members are required to assess the evolution and characteristics of this marker of pre-attentive processing. If mismatch negativity does provide an index of progressive changes in schizophrenia, and if they are found to be related to the structural imaging findings described above, this index may provide information about the mechanisms underlying such changes.
In contrast to the mismatch negativity which is pre-attentive, the P300 occurs to a stimulus that is actively detected and processed and is elicited by the oddball paradigm (for review see Salisbury et al, 2003). Because subjects actively attend to detect the rare occurrence of an infrequent target, deficits of or disruption to selective attention processes will disrupt the P300. Typically, patients with chronic schizophrenia show a robust reduction in P300 amplitude, which is trait-like (Jeon & Polich, 2001; Salisbury et al, 2003), and these deficits are considered to reflect impairments in sustained attention and higher level cognitive abilities, including working memory (Kimble et al, 2000). Symptom remission and atypical neuroleptics have been associated with some increase in P300 (Ford et al, 1994; Umbricht et al, 1998), although the impairment does not normalise (Salisbury et al, 2003). Further, Mathalon et al (2000) have shown that while auditory and visual P300s track symptom changes over time, only auditory P300s remained abnormal when patients were least symptomatic, suggesting that the latter was a trait marker. Examination of neuroleptic-naïve patients with first-episode psychosis indicates that the P300 abnormality is present prior to medication (Radwan et al, 1991; Hirayasu et al, 1998). The early studies of individuals at genetic high risk for developing schizophrenia are reviewed elsewhere (Friedman & Squires-Wheeler, 1994). These studies have found that P300 latencies are prolonged in these individuals (Schreiber et al, 1992; Friedman & Squires-Wheeler, 1994), although there are no reports comparing those who subsequently developed psychosis with those who did not. These studies are also consistent with P300 abnormalities identified in unaffected relatives of patients with schizophrenia (Blackwood et al, 1991; Frangou et al, 1997; Turetsky et al, 2000), which have also been related to neuropsychological deficits observed in patients and their relatives (Roxborough et al, 1993).
In the meta-analysis by Jeon & Polich (2001), smaller P300 amplitude was confirmed in patients with schizophrenia compared with control subjects and differed in its effect size topography across the midline and temporal electrode sites. These findings are consistent with evidence that the P300 is reduced over the midline and that there is a left temporal abnormality, which has been associated with reduced volume of the left posterior superior temporal gyrus (McCarley et al, 1993). Further, in patients with first-episode schizophrenia a smaller left temporal P300 was also associated with left posterior superior temporal gyrus and planum temporale volumes, whereas patients with affective psychosis did not show these impairments or associations (McCarley et al, 2002). Left superior temporal gyrus volumes have been associated with formal thought disorder (Shenton et al, 2001). This left temporal abnormality has been described in patients who ceased medication (Faux et al, 1993). A left-lateralised P300 deficit has also been described in schizotypal personality disorder (Niznikiewicz et al, 2000).
These studies of ERPs and their neurobiological correlates need to be examined in the recent high-risk or ultra-high-risk studies, and may provide trait/state indices, whereas longitudinal studies may provide insights about disease progression.
In vivo neurochemistry
Magnetic resonance spectroscopy (MRS) provides us with a non-invasive tool
to investigate metabolites in the living human brain. This technique overcomes
one major limitation of post-mortem analysis: the investigation of in
vivo brain metabolites during the peri-onset and early phases of the
illness and the investigation of medication effects on these metabolites. Much
MRS work has focused on investigating phosphorus-containing (31P
MRS) and proton-containing metabolites (1H MRS) (for reviews see
Keshavan et al, 2000; Stanley et al,
2000).
31P-MRS investigations in drug-naïve patients with first-episode psychosis suggest increased membrane breakdown at the onset of psychosis (Pettegrew et al, 1991; Stanley et al, 1995; Fukuzako et al, 1999) and in most studies there appears to be reduced membrane generation in early and chronic schizophrenia. Cell membrane changes occur prominently during cell generation and synaptogenesis, but also with degenerative processes, such as apoptotic elimination of dendrites and axons (pruning) and cell death. Cell membrane alterations of patients with schizophrenia are also well documented in peripheral and post-mortem brain tissue at different stages of the disorder (for review see Berger et al, 2002). Such findings may reflect either a reduction in glia-, synapto- and neurogenesis associated with chronic schizophrenia and/or accelerated programmed cell loss (apoptosis) and/or dendritic and axonal pruning at the onset of the disorder. Studies of adolescent offspring at increased genetic risk for schizophrenia show membrane alterations similar to those observed in patients with early schizophrenia (Klemm et al, 2001; Keshavan et al, 2003b); these changes are more pronounced in the at-risk adolescents who have already begun to manifest psychopathology (Keshavan et al, 2003b). Interestingly, patients with manic psychosis appear to have an increase in membrane precursors (Kato et al, 1993), which may reflect a compensatory increase in cell generation and/or synaptogenesis during manic exacerbation of psychotic disorders. Investigations using high-field 31P MRS (e.g. at 4T) in early psychosis are just emerging (Theberge et al, 2002).
Proton MRS provides us with a tool for measuring in vivo brain
metabolites, including N-acetylaspartate (NAA), creatine, choline,
myo-inositol, glutamine, glutamate, glutathione and -amino butyric acid
(GABA). N-acetylaspartate is mainly synthesised in neurons and is
therefore regarded as a putative marker for neuronal loss or dysfunction
(Urenjak et al,
1993; Rudkin & Arnold,
1999). However, NAA levels also depend on the capacity of glial
cells which are involved in the uptake and degradation of this metabolite
(Passani et al,
1998; Baslow, 2000; Bhakoo et al, 2001).
N-acetylaspartate is also a major acetyl-donor for the elongation of
long-chain fatty acids and is important for generation of membrane
phospholipids, the basic molecules of all cell membranes. Furthermore, NAA is
important for mitochondrial metabolism and excitatory neurotransmission
(Tsai & Coyle, 1995;
Lim et al, 1996).
Reductions in NAA peaks were found in most studies of patients with chronic schizophrenia encompassing several different brain regions (hippocampus, thalamus and frontal cortex), were variably present in first-degree relatives, and were associated with cortical atrophy and negative symptoms (for discussion and references see Keshavan et al, 2000; Vance et al, 2000). N-acetylaspartate reductions in the prefrontal cortex have been found to be associated with reduced physiological capacity for working memory as well as with exaggerated responses of dopamine neurons to amphetamine, a surrogate biological measure of positive symptoms (Weinberger et al, 2001). However, proton MRS studies in drug-naïve patients with first-episode psychosis have been less conclusive (Keshavan et al, 2000), and the data suggest that neuronal integrity in early phases of illness may still be intact and neuronal circuits only functionally impaired (Bartha et al, 1997, 1999). N-acetylaspartate reductions have been found to be correlated with increased illness duration (Ende et al, 2000) supporting the possibility of a progressive impairment of neuronal integrity as the illness unfolds. N-acetylaspartate changes may also represent dynamic measures of neuropathological change as a function of illness and/or change (Bertolino et al, 2001). Future longitudinal MRS studies before and after transition to psychosis may contribute to a better understanding of the relevance of NAA findings in the early phase of schizophrenia and related disorders.
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Several lines of future research are of promise in this burgeoning field.
First, advances in neuroimaging technology now allow us to examine the
neurobiology of psychosis in finer detail. High-field magnets (3T or
higher) allow better spatial resolution for structural imaging studies; better
neurochemical resolution for MRS may help investigation of key metabolites,
such as glutamate and GABA. Multimodal imaging studies combining functional
MRI and ERP techniques will increase temporal resolution and allow close
examination of disordered cognitive processes. Second, observations that the
early course of schizophrenia is associated with progressive changes in brain
structure and function highlight the importance of longitudinal studies of
individuals at ultra-high risk for developing psychosis who are not receiving
antipsychotic medication to track the underlying biology of transition to the
psychotic illnesses, as well as studies of patients with first-episode
psychosis to determine the biology of disease progression following illness
onset. Recognising these biological processes can eventually help to develop
phase-specific treatments that may be able to protect the vulnerable
individual from the emergence and/or progression of the illness. Third, the
observations of similar, albeit less severe, neurobiological changes in
relatives of patients with schizophrenia and other psychotic disorders suggest
that these studies may help us to better define the endophenotype of these
illnesses, and eventually elucidate the susceptibility genes for illness
onset, treatment response or outcome. Finally, neurobiological research in
early psychosis, to be successful, requires service structures that can access
adequate numbers of early psychosis patients. The recent emergence of
specialised early recognition and intervention services for early psychotic
disorders throughout the world (Edwards
& McGorry, 2002) will make neurobiological research in early
psychoses both timely and feasible.
![]() |
Clinical Implications and Limitations |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
LIMITATIONS
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Aleman, A., Hijman, R., de Haan, E. H., et al
(1999) Memory impairment in schizophrenia: a meta-analysis.
American Journal of Psychiatry,
156, 1358
1366.
Allin, M. & Murray, R. M. (2002) Schizophrenia: A neurodevelopmental or neurodegenerative disorder? Current Opinion in Psychiatry, 15, 9 15.[CrossRef]
Andersen, S. L. (2003) Trajectories of brain development: point of vulnerability or window of opportunity? Neuroscience and Biobehavioural Reviews, 27, 3 18.[CrossRef][Medline]
Baare, W. F., van Oel, C. J., Hulshoff Pol, H. E., et
al (2001) Volumes of brain structures in twins
discordant for schizophrenia. Archives of General
Psychiatry, 58, 33
40.
Barch, D. M., Carter, C. S., Braver, T. S., et al
(2001) Selective deficits in prefrontal cortex function in
medication-naive patients with schizophrenia. Archives of General
Psychiatry, 58, 280
288.
Bartha, R., Williamson, P. C., Drost, D. J., et al (1997) Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Archives of General Psychiatry, 54, 959 965.[Abstract]
Bartha, R., Al-Semaan, Y. M., Williamson, P. C., et al (1999) A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients. Biological Psychiatry, 45, 1403 1411.[CrossRef][Medline]
Baslow, M. H. (2000) Functions of N-acetyl-L-aspartate and N-acetyl-L-aspartylglutamate in the vertebrate brain: role in glial cell-specific signaling. Journal of Neurochemistry, 75, 453 459.[CrossRef][Medline]
Bayer, T. A., Falkai, P. & Maier, W. (1999) Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the two hit hypothesis. Journal of Psychiatric Research, 33, 543 548.[CrossRef][Medline]
Begre, S., Federspiel, A., Kiefer, C., et al (2003) Reduced hippocampal anisotropy related to anteriorization of alpha EEG in schizophrenia. Neuroreport, 14, 739 742.[CrossRef][Medline]
Berger, G. E., Wood, S. J., Pantelis, C., et al (2002) Implications of lipid biology for the pathogenesis of schizophrenia. Australian and New Zealand Journal of Psychiatry, 36, 355 366.[CrossRef][Medline]
Bertolino, A., Esposito, G., Callicott, J. H., et al
(2000) Specific relationship between prefrontal neuronal
N-acetylaspartate and activation of the working memory cortical
network in schizophrenia. American Journal of
Psychiatry, 157, 26
33.
Bertolino, A., Callicott, J. H., Mattay, V. S., et al (2001) The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biological Psychiatry, 49, 39 46.[CrossRef][Medline]
Bhakoo, K. K., Craig, T. J. & Styles, P. (2001) Developmental and regional distribution of aspartoacylase in rat brain tissue. Journal of Neurochemistry, 79, 211 220.[CrossRef][Medline]
Bilder, R. M., Goldman, R. S., Robinson, D., et al
(2000) Neuropsychology of first-episode schizophrenia:
initial characterization and clinical correlates. American Journal
of Psychiatry, 157, 549
559.
Bilder, R. M., Goldman, R. S., Volavka, J., et al
(2002) Neurocognitive effects of clozapine, olanzapine,
risperidone, and haloperidol in patients with chronic schizophrenia or
schizoaffective disorder. American Journal of
Psychiatry, 159, 1018
1028.
Blackwood, D. H., St Clair, D. M., Muir, W. J., et al (1991) Auditory P300 and eye tracking dysfunction in schizophrenic pedigrees. Archives of General Psychiatry, 48, 899 909.[Abstract]
Brewer, W. J., Pantelis, C., Anderson, V., et al
(2001) Stability of olfactory identification deficits in
neuroleptic-naive patients with first-episode psychosis. American
Journal of Psychiatry, 158, 107
115.
Brewer, W. J., Wood, S. J., McGorry, P. D., et al
(2003) Olfactory identification ability is impaired in
individuals at ultra high-risk for psychosis who later develop schizophrenia.
American Journal of Psychiatry,
160, 1790
1794.
Buhler, B., Hambrecht, M., Loffler, W., et al (2002) Precipitation and determination of the onset and course of schizophrenia by substance abuse a retrospective and prospective study of 232 population-based first illness episodes. Schizophrenia Research, 54, 243 251.[CrossRef][Medline]
Byrne, M., Hodges, A., Grant, E., et al (1999) Neuropsychological assessment of young people at high genetic risk for developing schizophrenia compared with controls: preliminary findings of the Edinburgh High Risk Study (EHRS). Psychological Medicine, 29, 1161 1173.[CrossRef][Medline]
Cahn, W., Hulshoff Pol, H. E., Lems, E. B. T. E., et al
(2002) Brain volume changes in first-episode schizophrenia: a
1-year follow-up study. Archives of General
Psychiatry, 59, 1002
1010.
Callicott, J. H. (2003) An expanded role for functional neuroimaging in schizophrenia. Current Opinion in Neurobiology, 13, 256 260.[CrossRef][Medline]
Callicott, J. H., Bertolino, A., Mattay, V. S., et al
(2000) Physiological dysfunction of the dorsolateral
prefrontal cortex in schizophrenia revisited. Cerebral
Cortex, 10, 1078
1092.
Cannon, T. D., van Erp, T. G., Huttunen, M., et al
(1998) Regional gray matter, white matter, and cerebrospinal
fluid distributions in schizophrenic patients, their siblings, and controls.
Archives of General Psychiatry,
55, 1084
1091.
Cannon, M., Caspi, A., Moffitt, T. E., et al
(2002) Evidence for early-childhood, pan-developmental
impairment specific to schizophreniform disorder: results from a longitudinal
birth cohort. Archives of General Psychiatry,
59, 449
456.
Carter, C. S., Mintun, M., Nichols, T., et al
(1997) Anterior cingulate gyrus dysfunction and selective
attention deficits in schizophrenia: [15O]H2OPET study
during single-trial Stroop task performance. American Journal of
Psychiatry, 154, 1670
1675.
Catts, S. V., Shelley, A. M., Ward, P. B., et al (1995) Brain potential evidence for an auditory sensory memory deficit in schizophrenia. American Journal of Psychiatry, 152, 213 219.[Abstract]
Censits, D. M., Ragland, J. D., Gur, R. C., et al (1997) Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study. Schizophrenia Research, 24, 289 298.[CrossRef][Medline]
Copolov, D., Velakoulis, D., McGorry, P., et al (2000) Neurobiological findings in early phase schizophrenia. Brain Research. Brain Research Reviews, 31, 157 165.[CrossRef][Medline]
Cornblatt, B. A. (2002) The New York high risk project to the Hillside recognition and prevention (RAP) program. American Journal of Medical Genetics, 114, 956 966.[CrossRef][Medline]
Cosway, R., Byrne, M., Clafferty, R., et al (2002) Sustained attention in young people at high risk for schizophrenia. Psychological Medicine, 32, 277 286.[Medline]
Davidson, L. L. & Heinrichs, R. W. (2003) Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Research, 122, 69 87.[CrossRef][Medline]
Edwards, J. & McGorry, P. D. (2002) Implementing Early Intervention in Psychosis: A Guide to Establishing Early Psychosis Services. London: Martin Dunitz.
Ende, G., Braus, D. F., Walter, S., et al (2000) Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia. Schizophrenia Research, 41, 389 395.[CrossRef][Medline]
Erlenmeyer-Kimling, L., Rock, D., Roberts, S. A., et al
(2000) Attention, memory, and motor skills as childhood
predictors of schizophrenia-related psychoses: The New York high-risk project.
American Journal of Psychiatry,
157, 1416
1422.
Faux, S. F., McCarley, R. W., Nestor, P. G., et al (1993) P300 topographic asymmetries are present in unmedicated schizophrenics. Electroencephalography and Clinical Neurophysiology, 88, 32 41.[CrossRef][Medline]
Feinberg, I. (1982) Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? Journal of Psychiatric Research, 17, 319 334.[CrossRef][Medline]
Feinberg, I. (1990) Cortical pruning and the development of schizophrenia. Schizophrenia Bulletin, 16, 567 570.[Medline]
Fletcher, P., McKenna, P. J., Friston, K. J., et al (1999) Abnormal cingulate modulation of fronto-temporal connectivity in schizophrenia. Neuroimage, 9, 337 342.[CrossRef][Medline]
Ford, J. M., White, P. M., Csernansky, J. G., et al (1994) ERPs in schizophrenia: effects of antipsychotic medication. Biological Psychiatry, 36, 153 170.[CrossRef][Medline]
Frangou, S., Sharma, T., Alarcon, G., et al (1997) Maudsley Family Study: II. Endogenous event-related potentials in familial schizophrenia. Schizophrenia Research, 23, 45 53.[CrossRef][Medline]
Friedman, D. & Squires-Wheeler, E. (1994) Event-related potentials (ERPs) as indicators of risk for schizophrenia. Schizophrenia Bulletin, 20, 63 74.[Medline]
Fukuzako, H., Fukuzako, T., Hashiguchi, T., et al
(1999) Changes in levels of phosphorous metabolites in
temporal lobes of drug-naive schizophrenic patients. American
Journal of Psychiatry, 156, 1205
1208.
Garver, D. L. (1987) Methodological issues facing the interpretation of high-risk studies: biological heterogeneity. Schizophrenia Bulletin, 13, 525 529.[Medline]
Gold, S., Arndt, S., Nopoulos, P., et al
(1999) Longitudinal study of cognitive function in
first-episode and recent-onset schizophrenia. American Journal of
Psychiatry, 156, 1342
1348.
Gur, R. E., Cowell, P., Turetsky, B. I., et al
(1998) A follow-up magnetic resonance imaging study of
schizophrenia. Relationship of neuroanatomical changes to clinical and
neurobehavioral measures. Archives of General
Psychiatry, 55, 145
152.
Hambrecht, M., Lammertink, M., Klosterkotter, J., et al
(2002) Subjective and objective neuropsychological
abnormalities in a psychosis prodrome clinic. British Journal of
Psychiatry, 181 (suppl. 43), s30
s37.
Harding, C. M., Brooks, G. W., Ashikaga, T., et al (1987) The Vermont longitudinal study of persons with severe mental illness: II. Long-term outcome of subjects who retrospectively met DSMIII criteria for schizophrenia. American Journal of Psychiatry, 144, 727 735.[Abstract]
Haznedar, M. M., Buchsbaum, M. S., Luu, C., et al (1997) Decreased anterior cingulate gyrus metabolic rate in schizophrenia. American Journal of Psychiatry, 154, 682 684.[Abstract]
Heinrichs, R. W. & Zakzanis, K. K. (1998) Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology, 12, 426 445.[CrossRef][Medline]
Hirayasu, Y., Asato, N., Ohta, H., et al (1998) Abnormalities of auditory event-related potentials in schizophrenia prior to treatment. Biological Psychiatry, 43, 244 253.[CrossRef][Medline]
Ho, B. C., Alicata, D., Ward, J., et al
(2003) Untreated initial psychosis: relation to cognitive
deficits and brain morphology in first-episode schizophrenia.
American Journal of Psychiatry,
160, 142
148.
Hoff, A. L., Riordan, H., ODonnell, D. W., et al (1992) Neuropsychological functioning of first-episode schizophreniform patients. American Journal of Psychiatry, 149, 898 903.[Abstract]
Hoff, A. L., Sakuma, M., Wieneke, M., et al
(1999) Longitudinal neuropsychological follow-up study of
patients with first-episode schizophrenia. American Journal of
Psychiatry, 156, 1336
1341.
Honey, G. D., Bullmore, E. T., Soni, W., et al
(1999) Differences in frontal cortical activation by a
working memory task after substitution of risperidone for typical
antipsychotic drugs in patients with schizophrenia. Proceedings of
the National Academy of Sciences USA,
96, 13432
13437.
Hulshoff Pol, H. E., Schnack, H. G., Bertens, M. G., et
al (2002) Volume changes in gray matter in patients with
schizophrenia. American Journal of Psychiatry,
159, 244
250.
Hutton, S. B., Puri, B. K., Duncan, L. J., et al (1998) Executive function in first-episode schizophrenia. Psychological Medicine, 28, 463 473.[CrossRef][Medline]
Javitt, D. C., Shelley, A. & Ritter, W. (2000a) Associated deficits in mismatch negativity generation and tone matching in schizophrenia. Clinical Neurophysiology, 111, 1733 1737.[CrossRef][Medline]
Javitt, D. C., Shelley, A. M., Silipo, G., et al
(2000b) Deficits in auditory and visual
context-dependent processing in schizophrenia: defining the pattern.
Archives of General Psychiatry,
57, 1131
1137.
Jeon, Y. W. & Polich, J. (2001) P300 asymmetry in schizophrenia: a meta-analysis. Psychiatry Research, 104, 61 74.[CrossRef][Medline]
Jessen, F., Fries, T., Kucharski, C., et al (2001) Amplitude reduction of the mismatch negativity in first-degree relatives of patients with schizophrenia. Neuroscience Letters, 309, 185 188.[CrossRef][Medline]
Johnstone, E. C., Crow, T. J., Frith, D. C., et al (1976) Cerebral ventricular size and cognitive impairment in schizophrenia. Lancet, 2, 924 926.[CrossRef][Medline]
Kato, T., Shioiri, T., Inubushi, T., et al (1993) Brain lithium concentrations measured with lithium-7 magnetic resonance spectroscopy in patients with affective disorders: relationship to erythrocyte and serum concentrations. Biological Psychiatry, 33, 147 152.[CrossRef][Medline]
Keshavan, M. S. & Schooler, N. R. (1992) First-episode studies of schizophrenia: criteria and characterization. Schizophrenia Bulletin, 18, 491 513.[Medline]
Keshavan, M. S. & Hogarty, G. E. (1999) Brain maturational processes and delayed onset in schizophrenia. Developmental Psychopathology, 11, 525 543.[CrossRef][Medline]
Keshavan, M. S., Bagwell, W. W. & Haas, G. L. (1994) Changes in caudate volume with neuroleptic treatment (letter). Lancet, 344, 1434 .[Medline]
Keshavan, M. S., Stanley, J. A. & Pettegrew, J. W. (2000) Magnetic resonance spectroscopy in schizophrenia: Methodological issues and findings, Part II. Biological Psychiatry, 48, 369 380.[CrossRef][Medline]
Keshavan, M. S., Dick, E., Mankowski, I., et al (2002a) Decreased left amygdala and hippocampal volumes in young offspring at risk for schizophrenia. Schizophrenia Research, 58, 173 183.[CrossRef][Medline]
Keshavan, M. S., Diwadkar, V. A., Spencer, S. M., et al (2002b) A preliminary functional magnetic resonance imaging study in offspring of schizophrenic parents. Progress in Neuropsychopharmacology and Biological Psychiatry, 26, 1143 1149.[CrossRef][Medline]
Keshavan, M. S., Haas, G., Miewald, J., et al (2003a) Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses. Schizophrenia Bulletin, 29, 757 769.[Medline]
Keshavan, M. S., Stanley, J. A., Montrose, D. M., et al (2003b) Prefrontal membrane phospholipid metabolism of child and adolescent offspring at risk for schizophrenia or schizoaffective disorder: an in vivo (31)P MRS study. Molecular Psychiatry, 8, 316 323.[CrossRef][Medline]
Kimble, M., Lyons, M., ODonnell, B., et al (2000) The effect of family status and schizotypy on electrophysiologic measures of attention and semantic processing. Biological Psychiatry, 47, 402 412.[CrossRef][Medline]
Kindermann, S. S., Karimi, A., Symonds, L., et al (1997) Review of functional magnetic resonance imaging in schizophrenia. Schizophrenia Research, 27, 143 156.[CrossRef][Medline]
Kirkpatrick, B., Buchanan, R. W., Ross, D. E., et al
(2001) A separate disease within the syndrome of
schizophrenia. Archives of General Psychiatry,
58, 165
171.
Klemm, S., Rzanny, R., Riehemann, S., et al (2001) Cerebral phosphate metabolism in first-degree relatives of patients with schizophrenia. American Journal of Psychiatry, 158, 958 960.[Medline]
Lawrie, S. M. & Abukmeil, S. S. (1998) Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. British Journal of Psychiatry, 172, 110 120.[Abstract]
Lawrie, S. M., Whalley, H. C., Abukmeil, S. S., et al (2001) Brain structure, genetic liability, and psychotic symptoms in subjects at high risk of developing schizophrenia. Biological Psychiatry, 49, 811 823.[Medline]
Liddle, P. F., Lane, C. J. & Ngan, E. T.
(2000) Immediate effects of risperidone on
cortico-striato-thalamic loops and the hippocampus. British Journal
of Psychiatry, 177, 402
407.
Lieberman, J. A., Perkins, D., Belger, A., et al (2001) The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biological Psychiatry, 50, 884 897.[CrossRef][Medline]
Lieberman, J., Charles, H. C., Sharma, T., et al (2003) Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia. Schizophrenia Research, 60, 293 .
Lim, K. O., Tew, W., Kushner, M., et al (1996) Cortical gray matter deficit is present in first episode schizophrenics. American Journal of Psychiatry, 153, 1548 1553.[Abstract]
Manoach, D. S., Press, D. Z., Thangaraj, V., et al (1999) Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI. Biological Psychiatry, 45, 1128 1137.[CrossRef][Medline]
Marsh, L., Suddath, R. L., Higgins, N., et al (1994) Medial temporal lobe structures in schizophrenia: relationship of size to duration of illness. Schizophrenia Research, 11, 225 238.[CrossRef][Medline]
Mathalon, D. H., Ford, J. M. & Pfefferbaum, A. (2000) Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study. Biological Psychiatry, 47, 434 449.[CrossRef][Medline]
McCarley, R. W., Shenton, M. E., ODonnell, B. F., et al (1993) Auditory P300 abnormalities and left posterior superior temporal gyrus volume reduction in schizophrenia. Archives of General Psychiatry, 50, 190 197.[Abstract]
McCarley, R. W., Salisbury, D. F., Hirayasu, Y., et al
(2002) Association between smaller left posterior superior
temporal gyrus volume on magnetic resonance imaging and smaller left temporal
P300 amplitude in first-episode schizophrenia. Archives of General
Psychiatry, 59, 321
331.
McCreadie, R. G., Thara, R., Padmavati, R., et al
(2002) Structural brain differences between never-treated
patients with schizophrenia, with and without dyskinesia, and normal control
subjects: a magnetic resonance imaging study. Archives of General
Psychiatry, 59, 332
336.
McGlashan, T. H. (1996) Early detection and intervention in schizophrenia: research. Schizophrenia Bulletin, 22, 327 345.[Medline]
McGorry, P. D. & McConville, S. B. (2000) Insight in psychosis. Harvard Mental Health Letters, 17, 3 5.
McGorry, P. D., Harrigan, S. M., Amminger, P., et al
(2001) Untreated initial psychosis. American
Journal of Psychiatry, 158, 1161
1163.
McGorry, P. D., Yung, A. R., Phillips, L. J., et al
(2002) Randomised controlled trial of interventions designed
to reduce the risk of progression to first-episode psychosis in a clinical
sample with subthreshold symptoms. Archives of General
Psychiatry, 59, 921
928.
Meltzer, H. Y. & McGurk, S. R. (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin, 25, 233 255.[Medline]
Michie, P. T., Innes-Brown, H., Todd, J., et al (2002) Duration mismatch negativity in biological relatives of patients with schizophrenia spectrum disorders. Biological Psychiatry, 52, 749 758.[CrossRef][Medline]
Miller, D. D., Andreasen, N. C., OLeary, D. S., et al (2001) Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. Biological Psychiatry, 49, 704 715.[CrossRef][Medline]
Miller, P., Byrne, M., Hodges, A., et al
(2002) Schizotypal components in people at high risk of
developing schizophrenia: early findings from the Edinburgh High-Risk Study.
British Journal of Psychiatry,
180, 179
184.
Mirsky, A. F., Ingraham, L. J. & Kugelmass, S. (1995) Neuropsychological assessment of attention and its pathology in the Israeli cohort. Schizophrenia Bulletin, 21, 193 204.[Medline]
Mohamed, S., Paulsen, J. S., OLeary, D., et al
(1999) Generalized cognitive deficits in schizophrenia: A
study of first episode patients. Archives of General
Psychiatry, 56, 749
754.
Moller, H. J. & Von Zerssen, D. (1995) Course and outcome of schizophrenia. In Schizophrenia (eds S. R. Hirsch & D. L. Weinberger). Oxford: Blackwell Science.
Murray, R. M. & Lewis, S. W. (1987) Is schizophrenia a neurodevelopmental disorder? (editorial) BMJ, 295, 681 682.[Medline]
Niznikiewicz, M. A., Voglmaier, M. M., Shenton, M. E., et al (2000) Lateralized P3 deficit in schizotypal personality disorder. Biological Psychiatry, 48, 702 705.[CrossRef][Medline]
Olney, J. W., Newcomer, J. W. & Farber, N. B. (1999) NMDA receptor hypofunction model of schizophrenia. Journal of Psychiatric Research, 33, 523 533.[CrossRef][Medline]
Pantelis, C., Wood, S. J. & Maruff, P. (2002) Schizophrenia. In Cognitive Deficits in Brain Disorders (ed. A. M. Owen), pp. 217 248. London: Martin Dunitz.
Pantelis, C., Velakoulis, D., McGorry, P. D., et al (2003a) Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet, 361, 281 288.[CrossRef][Medline]
Pantelis, C., Wood, S. J., Tarnawski, A., et al (2003b) Verbal paired associate learning in schizophrenia, schizophreniform psychosis and at risk mental state. Schizophrenia Research, 60 (suppl. 1), s151 s152.
Pantelis, C., Yucel, M., Wood, S. J., et al (2003c) Early and late neurodevelopmental disturbances in schizophrenia and their functional consequences. Australian and New Zealand Journal of Psychiatry, 37, 399 406.[CrossRef][Medline]
Parellada, E., Catafau, A. M., Bernardo, M., et al (1998) The resting and activation issue of hypofrontality: a single photon emission computed tomography study in neuroleptic-naive and neuroleptic-free schizophrenic female patients. Biological Psychiatry, 44, 787 790.[CrossRef][Medline]
Passani, L., Elkabes, S. & Coyle, J. T. (1998) Evidence for the presence of N-acetylaspartylglutamate in cultured oligodendrocytes and LPS activated microglia. Brain Research, 794, 143 145.[CrossRef][Medline]
Pettegrew, J. W., Keshavan, M. S., Panchalingam, K., et al (1991) Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Archives of General Psychiatry, 48, 563 568.[Abstract]
Pfefferbaum, A., Zipursky, R. B., Lim, K. O., et al (1988) Computed tomographic evidence for generalized sulcal and ventricular enlargement in schizophrenia. Archives of General Psychiatry, 45, 633 640.[Abstract]
Phillips, L. J., Yung, A. R., Yuen, H. P., et al (2002) Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics, 114, 929 937.[CrossRef][Medline]
Poulton, R., Caspi, A., Moffitt, T. E., et al
(2000) Childrens self-reported psychotic symptoms and
adult schizophreniform disorder: a 15-year longitudinal study.
Archives of General Psychiatry,
57, 1053
1058.
Proffitt, T., Pantelis, C., Brewer, W. J., et al (2000) The nature of the memory deficit in schizophrenia. Schizophrenia Research, 41, B280.
Radwan, M., Hermesh, H., Mintz, M., et al (1991) Event-related potentials in drug-naive schizophrenic patients. Biological Psychiatry, 29, 265 272.[CrossRef][Medline]
Riehemann, S., Volz, H. P., Stutzer, P., et al (2001) Hypofrontality in neuroleptic-naive schizophrenic patients during the Wisconsin Card Sorting Test A fMRI study. European Archives of Psychiatry and Clinical Neuroscience, 251, 66 71.[CrossRef][Medline]
Roxborough, H., Muir, W. J., Blackwood, D. H., et al (1993) Neuropsychological and P300 abnormalities in schizophrenics and their relatives. Psychological Medicine, 23, 305 314.[Medline]
Rudkin, T. M. & Arnold, D. L. (1999) Proton
magnetic resonance spectroscopy for the diagnosis and management of cerebral
disorders. Archives of Neurology,
56, 919
926.
Salisbury, D. F., Bonner-Jackson, A., Griggs, C. B., et al (2001) Mismatch negativity in schizophrenia: does MMN amplitude decline with disease duration? Biological Psychiatry, 49, s85 .
Salisbury, D. F., Shenton, M. E., Griggs, C. B., et al
(2002) Mismatch negativity in chronic schizophrenia and
first-episode schizophrenia. Archives of General
Psychiatry, 59, 686
694.
Salisbury, D. F., Krljes, S. & McCarley, R. W. (2003) Electrophysiology of schizophrenia. In Schizophrenia, 2nd edn (eds S. R. Hirsch & D. R. Weinberger). Oxford: Blackwell Science.
Saykin, A. J., Shtasel, D., Gur, R. E., et al (1994) Neuropsychological deficits in neuroleptic naive patients with first episode schizophrenia. Archives of General Psychiatry, 51, 124 131.[Abstract]
Schreiber, H., Stolz-Born, G., Kornhuber, H. H., et al (1992) Event-related potential correlates of impaired selective attention in children at high risk for schizophrenia. Biological Psychiatry, 32, 634 651.[CrossRef][Medline]
Schuepbach, D., Keshavan, M. S., Kmiec, J. A., et al (2002) Negative symptom resolution and improvements in specific cognitive deficits after acute treatment in first-episode schizophrenia. Schizophrenia Research, 53, 249 261.[CrossRef][Medline]
Sharma, T., Lancaster, E., Lee, D., et al (1998) Brain changes in schizophrenia. Volumetric MRI study of families multiply affected with schizophrenia the Maudsley Family Study 5. British Journal of Psychiatry, 173, 132 138.[Abstract]
Shenton, M. E., Dickey, C. C., Frumin, M., et al (2001) A review of MRI findings in schizophrenia. Schizophrenia Research, 49, 1 52.[Medline]
Stanley, J. A., Williamson, P. C., Drost, D. J., et al (1995) An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Archives of General Psychiatry, 52, 399 406.[Abstract]
Stanley, J. A., Pettegrew, J. W. & Keshavan, M. S. (2000) Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings I. Biological Psychiatry, 48, 357 368.[CrossRef][Medline]
Stevens, A. A., Goldman-Rakic, P. S., Gore, J. C., et
al (1998) Cortical dysfunction in schizophrenia during
auditory word and tone working memory demonstrated by functional magnetic
resonance imaging. Archives of General Psychiatry,
55, 1097
1103.
Sun, D., Stuart, G. W., Wood, S. J., et al (2003) Progressive frontal lobe reduction in first episode psychosis. Schizophrenia Research, 60, 208.
Theberge, J., Bartha, R., Drost, D. J., et al
(2002) Glutamate and glutamine measured with 4.0 T proton MRS
in never-treated patients with schizophrenia and healthy volunteers.
American Journal of Psychiatry,
159, 1944
1946.
Tsai, G. & Coyle, J. T. (1995) N-acetylaspartate in neuropsychiatric disorders. Progress in Neurobiology, 46, 531 540.[CrossRef][Medline]
Turetsky, B. I., Cannon, T. D. & Gur, R. E. (2000) P300 subcomponent abnormalities in schizophrenia: III. Deficits in unaffected siblings of schizophrenic probands. Biological Psychiatry, 47, 380 390.[CrossRef][Medline]
Umbricht, D., Javitt, D., Novak, G., et al (1998) Effects of clozapine on auditory event-related potentials in schizophrenia. Biological Psychiatry, 44, 716 725.[CrossRef][Medline]
Umbricht, D., Schmid, L., Koller, R., et al
(2000) Ketamine-induced deficits in auditory and visual
context-dependent processing in healthy volunteers: implications for models of
cognitive deficits in schizophrenia. Archives of General
Psychiatry, 57, 1139
1147.
Umbricht, D., Koller, R., Schmid, L., et al (2003) How specific are deficits in mismatch negativity generation to schizophrenia? Biological Psychiatry, 53, 1120 1131.[CrossRef][Medline]
Urenjak, J., Williams, S. R., Gadian, D. G., et al (1993) Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. Journal of Neuroscience, 13, 981 989.[Abstract]
Vance, A. L., Velakoulis, D., Maruff, P., et al (2000) Magnetic resonance spectroscopy and schizophrenia: what have we learnt? Australian and New Zealand Journal of Psychiatry, 34, 14 25.[CrossRef][Medline]
Velakoulis, D. & Pantelis, C. (1996) What have we learned from functional imaging studies in schizophrenia? The role of frontal, striatal and temporal areas. Australian and New Zealand Journal of Psychiatry, 30, 195 209.[Medline]
Velakoulis, D., Wood, S. J., McGorry, P. D., et al (2000) Evidence for progression of brain structural abnormalities in schizophrenia: beyond the neurodevelopmental model. Australian and New Zealand Journal of Psychiatry, 34, (suppl.) s113 s126.[CrossRef][Medline]
Weickert, T. W., Goldberg, T. E., Gold, J. M., et al
(2000) Cognitive impairments in patients with schizophrenia
displaying preserved and compromised intellect. Archives of General
Psychiatry, 57, 907
913.
Weinberger, D. R. (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry, 44, 660 669.[Abstract]
Weinberger, D. R. & McClure, R. K. (2002)
Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry:
what is happening in the schizophrenic brain? Archives of General
Psychiatry, 59, 553
558.
Weinberger, D. R., Torrey, E. F., Neophytides, A. N., et al (1979) Structural abnormalities in the cerebral cortex of chronic schizophrenic patients. Archives of General Psychiatry, 36, 935 939.[Abstract]
Weinberger, D. R., Berman, K. F., Suddath, R. L., et al (1992) Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: An MRI and regional cerebral blood flow study of discordant monozygotic twins. American Journal of Psychiatry, 149, 890 897.[Abstract]
Weinberger, D. R., Egan, M. F., Bertolino, A., et al (2001) Prefrontal neurons and the genetics of schizophrenia. Biological Psychiatry, 50, 825 844.[CrossRef][Medline]
Weintraub, S. (1987) Risk factors in schizophrenia: the Stony Brook High-Risk Project. Schizophrenia Bulletin, 13, 439 450.[Medline]
Wolf, L. E. & Cornblatt, B. A. (1996) Neuropsychological functioning in children at risk for schizophrenia. In Schizophrenia: A Neuropsychological Perspective (ed. T. R. E. Barnes), pp. 161182. Chichester, UK: John Wiley.
Wood, S. J., Velakoulis, D., Smith, D., et al (2001) A longitudinal study of hippocampal volume in first episode psychosis and chronic schizophrenia. Schizophrenia Research, 51, 37 46.
Wood, S. J., Proffitt, T., Mahony, K., et al (2002) Visuospatial memory and learning in first-episode schizophreniform psychosis and established schizophrenia: a functional correlate of hippocampal pathology? Psychological Medicine, 32, 429 438.[CrossRef][Medline]
Wood, S. J., Pantelis, C., Proffitt, T., et al (2003) Spatial working memory ability is a marker of risk-for-psychosis. Psychological Medicine, 33, 1239 1247.[CrossRef][Medline]
Wyatt, R. J. (1991) Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia. Schizophrenia Research, 5, 201 202.[CrossRef][Medline]
Yucel, M., Pantelis, C., Stuart, G. W., et al (2002) Anterior cingulate activation during Stroop task performance: a PET to MRI coregistration study of individual patients with schizophrenia. Americal Journal of Psychiatry, 159, 251 254.[CrossRef]
Yung, A. R., McGorry, P. D., McFarlane, C. A., et al (1996) Monitoring and care of young people at incipient risk of psychosis. Schizophrenia Bulletin, 22, 283 303.[Medline]
Yung, A. R., Phillips, L. J., McGorry, P. D., et al (1998) Prediction of psychosis: A step towards indicated prevention of schizophrenia. British Journal of Psychiatry, 172(suppl. 33), s14 s20.
Yung, A. R., Phillips, L. J., Yuen, H. P., et al (2003) Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophrenia Research, 60, 21 32.[CrossRef][Medline]
Zipursky, R. B., Lim, K. O., Rosenbloom, M., et al (1988) Differing effects of duration of illness on CT findings in alcoholism and schizophrenia. Psychopharmacology Bulletin, 24, 495 500.[Medline]
Zipursky, R. B., Lambe, E. K., Kapur, S., et al
(1998) Cerebral gray matter volume deficits in first episode
psychosis. Archives of General Psychiatry,
55, 540
546.
HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |